In conclusion, we have constructed a fusion protein that retained its p53-dependent DNA binding activity in vitro and is internalized via its C2IN domain into the cytosol of various cancer cell lines using the C2IIa binding/translocation component. The gene discussed is TP53; the disease is cancer.